EcoGen Biosciences Acquires General Processing LLC

Generation Hemp Acquires Halcyon Thruput, LLC for ~$5.1 Million

March 9, 2020

Agriculture

Generation Hemp, Inc. has signed definitive agreements to acquire 100% of the assets/ownership interest of Halcyon Thruput, LLC for approximately $5.1 million (paid $2.5M in restricted common stock and $2.6M in cash), with additional contingent consideration payable to the parent OZC Agriculture Ky, LP. Halcyon operates a 48,000 sq. ft. hemp post‑harvest facility in Hopkinsville, Kentucky (processing ~10,000 wet pounds/hour) and projects about $10 million revenue for calendar year 2020; the co‑founders will remain as employees under multi‑year agreements.

Nexus Agriscience Acquires Hemp Division and IP Portfolio from Biotech Institute

January 27, 2026

Biotechnology

Nexus Agriscience has acquired the hemp division and intellectual property portfolio of Biotech Institute, internalizing genetics, germplasm, and research talent to expand its molecular farming platform. The transaction brings issued and pending patents, proprietary germplasm, seed inventory, and key personnel into Nexus to accelerate development of hemp-derived natural ingredients for flavor, fragrance, and functional markets.

Cannabinoid Biosciences Acquires CannabidiolHemp

November 25, 2019

Consumer Products

Cannabinoid Biosciences, Inc., a California-based biopharmaceutical subsidiary of Kid Castle, has acquired CannabidiolHemp (CannabidiolHemp.net), a CBD quality aggregator and validator. The purchase is the first of multiple planned acquisitions intended to build a vertically integrated CBD distribution and supply-chain business across the United States and Canada.

Ampersand Capital Partners Invests in Genezen Laboratories

January 5, 2021

Biotechnology

Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.

GenCanna Acquires CBD Capital Ltd

September 1, 2021

Manufacturing

GenCanna, a Kentucky-based vertically integrated CBD manufacturer, has acquired London-based CBD Capital Ltd to expand its bulk ingredient and finished-goods operations across the United Kingdom, the European Union and other global markets. The deal broadens GenCanna’s formulation and distribution capabilities in Europe; CBD Capital CEO Hassan Akhtar will remain in his role.

Genezen Acquires uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

July 1, 2024

Biotechnology

Genezen has acquired uniQure's commercial gene therapy manufacturing operations and licensed viral-vector facility in Lexington, Massachusetts. The deal (funded in part by growth equity from Ampersand Capital Partners) transfers a commercially licensed AAV-capable manufacturing site and team to Genezen and includes strategic supply agreements to support uniQure's clinical portfolio and CSL Behring's commercial HEMGENIX product.